triple glp 1 gip glucagon receptor agonist Courtesy ref no. 43-Schematic demonstrating the working principle, Why Retatrutide is different 👇

Argentina and Colombia apply strict prior-authorization hurdles that lengthen initiation and depress uptake, effectively confining large segments of the Latin America GLP-1 agonists market to private payers

A 2025 Stanford University interview with psychiatrist Anna Lembke touches on positive connections between the dopamine-stabilizing effects of GLP-1 medications on food addictions and the similar needs of patients with other drug addiction issues

LC, locus ceruleus

The company now claimed that MariTide only resulted in up to 16% average weight loss among study participants, not 20% as previously claimed. The discrepancy is down to how the results were calculated

doi: 10.1016/j.brainres.2019.146562 [DOI] [PubMed] [Google Scholar] 163.Bornebusch AB, Fink-Jensen A, Wrtwein G, et al

Six models were fit with BrAC, perceived drunkenness, alcohol craving, appetite, blood glucose, and nausea scores as dependent variables, respectively (Supplemental Table 2)